So, there is a company called Intelligent Bio Solutions that makes things to help test drugs. They are doing really well and selling more of their products, so they expect to make a lot more money than last year. This is making people excited and the price of their shares is going up a lot. Read from source...

- The title is misleading and sensationalized. It implies that the shares are skyrocketing because of some exceptional performance or news, but it does not provide any evidence or data to support this claim. A more accurate title could be "Why Intelligent Bio Solutions Shares Are Rising Today".
- The article lacks depth and analysis. It only provides a brief summary of the company's revenue projections for H2 2023, without explaining how they were calculated or what factors influenced them. It also does not mention any challenges, risks, or uncertainties that the company might face in achieving these goals.
- The article quotes the CEO without providing any context or background information about him or his credibility. It also does not include any independent sources or expert opinions to corroborate or challenge his statements. This creates a one-sided and potentially biased perspective of the company's performance and outlook.
- The article mentions the reverse stock split as a positive event, without acknowledging its potential drawbacks or consequences. A reverse stock split can artificially inflate the share price, but it can also dilute the value of existing shares and attract unwanted attention from regulators or short sellers. It is not a clear indication of the company's financial health or growth prospects.
- The article ends with a vague reference to "stories that matter" and "why it's mo", without explaining what these terms mean or how they relate to the company or its shares. This creates confusion and ambiguity for the readers, who might wonder what the purpose of the article is and why they should care about the company.

1. Buy Intelligent Bio Solutions shares as they are undervalued based on the expected revenue growth of 337% YoY for H2 2023, driven by expanding product sales. The company has a strong product portfolio with increasing demand in new markets such as Asia-Pacific.